The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1186
July 5, 2004
View Complete Issue         Table of Contents 2019 
Amlodipine/Atorvastatin (Caduet)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Amlodipine/Atorvastatin (Caduet)
July 5, 2004 (Issue: 1186)
Caduet (Pfizer), a combination of the calcium-channel blocker amlodipine (Norvasc - Pfizer) and the HMG-CoA reductase inhibitor (statin) atorvastatin (Lipitor - Pfizer), is now available in the US. It was approved by the FDA for use in patients with...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Amlodipine/Atorvastatin (Caduet)
Article code: 1186b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.